CT-guided 125I brachytherapy for recurrent ovarian cancer

// Ping Liu 1 , Lina Tong 1 , Bin Huo 2 , Dong Dai 3 , Wenxin Liu 4 , Ke Wang 4 , Ying Wang 1 , Zhi Guo 1 and Hong Ni 1 1 Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China 2 Department of Oncology, The Second Hospital of Tianjin Medical University, Tianjin, People’s Republic of China 3 Department of Molecule Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China 4 Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China Correspondence to: Hong Ni, email: // Zhi Guo, email: // Keywords : 125 I seeds, brachytherapy, recurrent ovarian cancer Received : February 17, 2016 Accepted : February 20, 2017 Published : March 04, 2017 Abstract This retrospective study was to evaluate the local control and survival of 125 I brachytherapy for recurrent ovarian cancer. 52 125 I brachytherapy procedures were performed in 47 patients with 51 recurrent ovarian cancer lesions. The follow-up period was 1-55 months (median 12 months). The local control rate (LC) of 3, 6, 12, 24 and 36 months was 93.3%, 77.7%, 58.9%, 38.7% and 19.3%, respectively. Patients with tumor size ≤ 4cm (85.7% vs 40.0%, P = 0.037) and actual D90 between 110 to 130Gy (47.4% vs 66.7% vs 62.5%, P = 0.029) had better LC. The 1, 2 and 3 years of overall survival (OS) was 79.3%, 63.0% and 52.5%, respectively. The poor performance status (HR 3.821, 95% CI 1.383-10.555; P = 0.010), concurrent distant metastasis (HR 9.222, 95% CI 1.710-49.737; P = 0.010) and large postoperative residual tumor size (HR 6.157, 95% CI 1.438-26.367; P = 0.014) were closely correlated with a poor OS. Our data indicate thatCT-guided 125 I brachytherapy is an effective and safe modality for the local treatment of recurrent ovarian cancer.